In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy

Cancer Science

Volumn 101, Issue 2, 2010, Pages 474-481

  Davydova, Julia ^a   Gavrikova, Tatyana ^b   Brown, Eric J ^a   Luo, Xianghua ^c   Curiel, David T ^b   Vickers, Selwyn M ^a   Yamamoto, Masato ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; CYCLOOXYGENASE 2; LUCIFERASE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR; TUMOR CELL DESTRUCTION; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

EID: 75649147870     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01407.x     Document Type: Article

References (31)

1. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000, 18:723-7.
2. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005, 74:711-38.
3. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001, 1:525-38.
4. Reid T, Galanis E, Abbruzzese J. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002, 62:6070-9.
5. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007, 28:42-58.
6. Yamamoto M, Curiel DT. Cancer gene therapy. Technol Cancer Res Treat 2005, 4:315-30.
7. DeWeese TL, van der Poel H, Li S. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61:7464-72.
8. Khuri FR, Nemunaitis J, Ganly I. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-85.
9. Nemunaitis J, Ganly I, Khuri F. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000, 60:6359-66.
10. Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 2005, 65:10154-8.
11. Zinn KR, Chaudhuri TR, Szafran AA. Noninvasive bioluminescence imaging in small animals. Ilar J 2008, 49:103-15.
12. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther 2001, 4:297-306.
13. Ray P, Gambhir SS. Noninvasive imaging of molecular events with bioluminescent reporter genes in living subjects. Methods Mol Biol 2007, 411:131-44.
14. Ishikawa TO, Jain NK, Taketo MM, Herschman HR. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. Mol Imaging Biol 2006, 8:171-87.
15. Liang Q, Yamamoto M, Curiel DT, Herschman HR. Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene. Mol Imaging Biol 2004, 6:395-404.
16. Mittal SK, McDermott MR, Johnson DC, Prevec L, Graham FL. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993, 28:67-90.
17. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virol 2003, 305:378-87.
18. Mittal SK, Bett AJ, Prevec L, Graham FL. Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial beta-galactosidase genes as reporters. Virol 1995, 210:226-30.
19. Lichtenstein DL, Spencer JF, Doronin K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009, 16:644-54.
20. Yamamoto M, Davydova J, Wang M. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003, 125:1203-18.
21. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 2004, 64:4319-27.
22. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001, 3:385-94.
23. Alemany R. Designing adenoviral vectors for tumor-specific targeting. Methods Mol Biol 2009, 542:57-74.
24. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001, 8:89-98.
25. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007, 7:133-9.
26. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-87.
27. Gambhir SS. Molecualr imaging of cancer: from molecules to humans. Introduction. J Nucl Med 2008, 49(Suppl 2):1S-4S.
28. Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 2004, 3:105-16.
29. Carlson SK, Classic KL, Hadac EM. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol 2009, 192:279-87.
30. Kishimoto H, Zhao M, Hayashi K. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A 2009, 106:14514-7.
31. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005, 12:673-81.